280 related articles for article (PubMed ID: 32767049)
1. Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms.
Song XL; Ren JL; Zhao D; Wang L; Ren H; Niu J
Eur Radiol; 2021 Jan; 31(1):368-378. PubMed ID: 32767049
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of Ovarian Neoplasms Using Nomogram in Combination With Ultrasound Image-Based Radiomics Signature and Clinical Factors.
Qi L; Chen D; Li C; Li J; Wang J; Zhang C; Li X; Qiao G; Wu H; Zhang X; Ma W
Front Genet; 2021; 12():753948. PubMed ID: 34650603
[No Abstract] [Full Text] [Related]
3. Radiomics Based on Multimodal MRI for the Differential Diagnosis of Benign and Malignant Breast Lesions.
Zhang Q; Peng Y; Liu W; Bai J; Zheng J; Yang X; Zhou L
J Magn Reson Imaging; 2020 Aug; 52(2):596-607. PubMed ID: 32061014
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study.
Zhang H; Mao Y; Chen X; Wu G; Liu X; Zhang P; Bai Y; Lu P; Yao W; Wang Y; Yu J; Zhang G
Eur Radiol; 2019 Jul; 29(7):3358-3371. PubMed ID: 30963272
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-based deep learning radiomics model for differentiating benign, borderline, and malignant ovarian tumours: a multi-class classification exploratory study.
Du Y; Guo W; Xiao Y; Chen H; Yao J; Wu J
BMC Med Imaging; 2024 Apr; 24(1):89. PubMed ID: 38622546
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics.
Liu Z; Feng B; Li C; Chen Y; Chen Q; Li X; Guan J; Chen X; Cui E; Li R; Li Z; Long W
J Magn Reson Imaging; 2019 Sep; 50(3):847-857. PubMed ID: 30773770
[TBL] [Abstract][Full Text] [Related]
7. Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors.
Li HM; Feng F; Qiang JW; Zhang GF; Zhao SH; Ma FH; Li YA; Gu WY
Abdom Radiol (NY); 2018 Nov; 43(11):3132-3141. PubMed ID: 29556691
[TBL] [Abstract][Full Text] [Related]
8. Application of BOLD
Deng Y; Pan L; Xing W; Zhou Z; Chen J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):1010-1017. PubMed ID: 34707012
[TBL] [Abstract][Full Text] [Related]
9. An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies.
Pötsch N; Dietzel M; Kapetas P; Clauser P; Pinker K; Ellmann S; Uder M; Helbich T; Baltzer PAT
Eur Radiol; 2021 Aug; 31(8):5866-5876. PubMed ID: 33744990
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of triple negative breast cancer based on DCE-MRI multi-phase full-volume ROI clinical radiomics model.
Qi X; Wang W; Pan S; Liu G; Xia L; Duan S; He Y
Acta Radiol; 2024 Feb; 65(2):173-184. PubMed ID: 38017694
[TBL] [Abstract][Full Text] [Related]
11. Application Values of 2D and 3D Radiomics Models Based on CT Plain Scan in Differentiating Benign from Malignant Ovarian Tumors.
Li S; Liu J; Xiong Y; Han Y; Pang P; Luo P; Fan B
Biomed Res Int; 2022; 2022():5952296. PubMed ID: 35224097
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of Benign from Malignant Adnexal Masses by Dynamic Contrast-Enhanced MRI (DCE-MRI): Quantitative and Semi-quantitative analysis at 3-Tesla MRI.
Gity M; Parviz S; Saligheh Rad H; Fathi Kazerooni A; Shirali E; Shakiba M; Baikpour M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1073-1079. PubMed ID: 31030476
[TBL] [Abstract][Full Text] [Related]
13. MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes.
Qian L; Ren J; Liu A; Gao Y; Hao F; Zhao L; Wu H; Niu G
Eur Radiol; 2020 Nov; 30(11):5815-5825. PubMed ID: 32535738
[TBL] [Abstract][Full Text] [Related]
14. T2-weighted MRI-based radiomics for discriminating between benign and borderline epithelial ovarian tumors: a multicenter study.
Wei M; Zhang Y; Bai G; Ding C; Xu H; Dai Y; Chen S; Wang H
Insights Imaging; 2022 Aug; 13(1):130. PubMed ID: 35943620
[TBL] [Abstract][Full Text] [Related]
15. Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions.
Xu M; Fang M; Zou J; Yang S; Yu D; Zhong L; Hu C; Zang Y; Dong D; Tian J; Fang X
Eur J Radiol; 2019 May; 114():38-44. PubMed ID: 31005174
[TBL] [Abstract][Full Text] [Related]
16. Two-dimensional and three-dimensional T2 weighted imaging-based radiomic signatures for the preoperative discrimination of ovarian borderline tumors and malignant tumors.
Liu X; Wang T; Zhang G; Hua K; Jiang H; Duan S; Jin J; Zhang H
J Ovarian Res; 2022 Feb; 15(1):22. PubMed ID: 35115022
[TBL] [Abstract][Full Text] [Related]
17. Characterization of spatiotemporal changes for the classification of dynamic contrast-enhanced magnetic-resonance breast lesions.
Milenković J; Hertl K; Košir A; Zibert J; Tasič JF
Artif Intell Med; 2013 Jun; 58(2):101-14. PubMed ID: 23548472
[TBL] [Abstract][Full Text] [Related]
18. Multi-modality radiomics nomogram based on DCE-MRI and ultrasound images for benign and malignant breast lesion classification.
Liu X; Zhang J; Zhou J; He Y; Xu Y; Zhang Z; Cao G; Miao H; Chen Z; Zhao Y; Jin X; Wang M
Front Oncol; 2022; 12():992509. PubMed ID: 36531052
[TBL] [Abstract][Full Text] [Related]
19. Texture Analysis of Three-Dimensional MRI Images May Differentiate Borderline and Malignant Epithelial Ovarian Tumors.
Ye R; Weng S; Li Y; Yan C; Chen J; Zhu Y; Wen L
Korean J Radiol; 2021 Jan; 22(1):106-117. PubMed ID: 32932563
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging based radiomics signature for the preoperative discrimination of stage I-II and III-IV head and neck squamous cell carcinoma.
Ren J; Tian J; Yuan Y; Dong D; Li X; Shi Y; Tao X
Eur J Radiol; 2018 Sep; 106():1-6. PubMed ID: 30150029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
